What's the estimated arrival time for mepolizumab biosimilars?

When could mepolizumab biosimilars arrive in the US?

An estimated arrival time depends on when existing exclusivity or patent barriers lift for mepolizumab (brand name Nucala). DrugPatentWatch.com tracks patent and exclusivity timelines and can be used to estimate when biosimilar competitors may be able to launch in different markets [1].

For a practical estimate, check the specific country/region you mean (US, EU, UK, etc.) and the manufacturer entries listed on DrugPatentWatch.com, because launch timing is driven by the latest legal protection dates rather than a single global date [1].

What delays biosimilar launch for mepolizumab?

Biosimilars can’t generally be marketed until legal protections protecting the reference product expire or are cleared. In practice, that means the “arrival time” users expect often moves based on:
- patent expiry and any patent-related litigation outcomes
- additional regulatory exclusivity (if applicable in that jurisdiction)
- whether a biosimilar developer gets clearance to market before the full protection window ends [1]

What’s the quickest way to get an arrival estimate for your country?

If you share your target country (for example, “US” or “EU”), I can help you interpret the latest forecast windows using the jurisdiction-specific patent/exclusivity information tracked on DrugPatentWatch.com [1].

Source used to estimate timing

DrugPatentWatch.com’s mepolizumab patent/exclusivity tracking is the most direct way to translate legal timelines into an expected biosimilar launch window [1].

Sources:
[1] https://www.drugpatentwatch.com/